Evidence mapPaperPMID 41681968Full record

ReviewCancers2026

Decoding Microbiota in Genitourinary Oncology: Biological Mechanisms and Clinical Implications-A Narrative Review.

Irene Caramella, Chiara Abeni, Sara Cherri, Chiara Ogliosi, Tonino Morena, Giacomo Galvagni, Fausto Meriggi, Alberto Zaniboni

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Irene CaramellaDepartment of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy.ORCID 0000-0001-7422-0119
Chiara AbeniDepartment of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy.
Sara CherriDepartment of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy.
Chiara OgliosiDepartment of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy.
Tonino MorenaDepartment of Urology, Fondazione Poliambulanza, 25124 Brescia, Italy.ORCID 0000-0003-4958-3780
Giacomo GalvagniDepartment of Urology, Fondazione Poliambulanza, 25124 Brescia, Italy.
Fausto MeriggiDepartment of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy.
Alberto ZaniboniDepartment of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genitourinary malignancies are characterized by marked heterogeneity in tumor biology, clinical behavior and therapeutic outcomes. Despite significant progress in surgical and systemic treatments, resistance to therapy remains a major challenge, highlighting the need to identify additional host-related determinants of disease progression and treatment response. Within this framework, converging experimental and clinical evidence indicates that host-associated microbial ecosystems may influence key biological processes involved in tumor-host interactions, including immune modulation, metabolic regulation and inflammatory pathways. Altered microbial profiles have been associated with oncogenic signaling, changes in the tumor microenvironment and differences in clinical benefit from systemic therapies, particularly immunotherapeutic approaches. This review brings together preclinical, translational and clinical evidence on the involvement of microbiota in renal, prostate, bladder and testicular cancers, with attention to biological mechanisms and clinically meaningful correlations with disease characteristics. While current data are largely observational, early interventional studies suggest that modulation of microbial ecosystems may influence therapeutic activity in selected clinical settings. Collectively, these findings support microbiota as a relevant component of genitourinary cancer biology with potential implications for precision medicine approaches.

Indexed as

genitourinary malignanciesgut–urogenital axisimmune checkpoint inhibitorsintratumoral microbiomemicrobiotaprecision oncology

Identifiers

PMID41681968
PMCPMC12897120

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.